OEAP West 2026 Recap: Expanded Access Enters a New Era of Operational Excellence
The conversations at Operationalize: Expanded Access Programs (OEAP) West in San Francisco made one thing abundantly clear: Expanded Access Programs (EAPs) are no longer viewed as exceptional, one-off initiatives. They have become strategic, global programs that require the same level of governance, technology, and cross-functional collaboration as any other critical development function.
Over three days, pharmaceutical and biotechnology leaders gathered to discuss how organizations are scaling patient access while navigating increasingly complex regulatory, operational, and ethical challenges. From Medical Affairs and Regulatory Affairs to Clinical Operations and Supply Chain, attendees shared practical experiences and emerging best practices for building sustainable Expanded Access and Post-Trial Access programs.
Five Themes Defined the Conference
1. Expanded Access Is Becoming a Strategic Capability
One of the strongest messages throughout the conference was that Expanded Access is moving upstream.
Rather than waiting until late-stage development or responding reactively to individual patient requests, companies are incorporating Expanded Access planning much earlier in the product lifecycle. This proactive approach allows organizations to better anticipate operational requirements, align internal stakeholders, and create scalable governance models.
As more therapies target rare diseases, precision medicine, and oncology, sponsors recognize that early planning improves both patient access and organizational readiness.
2. Cross-Functional Collaboration Is Essential
Running a successful Expanded Access Program now requires far more than Medical Affairs alone.
Conference sessions repeatedly emphasized the need for close collaboration between:
Medical Affairs
Clinical Operations
Regulatory Affairs
Clinical Supply
Legal and Compliance
Pharmacovigilance
Quality
Commercial planning
Organizations that establish clear ownership, standardized workflows, and shared visibility across these functions are better positioned to launch programs efficiently while maintaining compliance.
Technology is increasingly serving as the connective tissue between these teams, replacing disconnected spreadsheets, emails, and manual tracking with centralized workflows.
3. Global Programs Demand Greater Operational Sophistication
As Expanded Access continues to expand internationally, sponsors face significant differences in country-specific regulations, import requirements, ethics approvals, reimbursement considerations, and reporting obligations.
Managing these complexities manually is becoming increasingly difficult.
Conference discussions highlighted the growing need for configurable platforms that allow organizations to standardize global governance while maintaining the flexibility to support local regulatory requirements.
The industry's focus has shifted from simply managing requests to building repeatable, scalable operational processes that can support global growth.
4. Real-World Data Is Becoming Increasingly Valuable
Several presentations explored how data collected through Expanded Access Programs can generate meaningful operational and clinical insights when collected appropriately and ethically.
Sponsors are increasingly looking beyond simply delivering treatment. They are also considering how structured data collection can help:
Better understand patient outcomes
Improve future program design
Support evidence generation
Inform regulatory decision-making
Strengthen post-trial planning
As the industry matures, organizations are looking for ways to capture high-quality data without creating unnecessary burden for physicians or delaying patient access.
5. Technology Is No Longer Optional
Perhaps the most consistent takeaway from OEAP West was that manual processes are reaching their limits.
As programs grow in complexity, organizations need platforms that can automate workflows, improve collaboration, maintain complete audit trails, and provide real-time visibility into program performance.
Digital transformation is no longer viewed as a future initiative—it is becoming foundational to delivering compliant, scalable Expanded Access Programs.
MedaSystems at OEAP West
As a sponsor of OEAP West, MedaSystems had the opportunity to engage with pharmaceutical leaders who are actively shaping the future of Expanded Access.
Across conversations with customers, partners, and industry peers, many of the same operational challenges surfaced repeatedly:
Managing increasingly complex global programs
Reducing manual administrative work
Improving collaboration across internal teams and external partners
Standardizing processes while maintaining flexibility
Preparing programs to scale as demand grows
These discussions reinforce the industry's growing need for modern technology designed specifically for Expanded Access, Post-Trial Access, and Investigator-Initiated Studies.
At MedaSystems, we remain committed to helping pharmaceutical organizations modernize these critical programs through configurable workflows, centralized collaboration, real-time visibility, and validated technology that supports global compliance while keeping the focus where it belongs—on patients.
Looking Ahead
OEAP West demonstrated that Expanded Access continues to evolve from an operational necessity into a strategic capability.
Organizations that invest today in scalable processes, collaborative governance, and purpose-built technology will be best positioned to meet growing patient demand while navigating an increasingly complex global regulatory landscape.
The future of Expanded Access will be defined not only by faster access to life-changing therapies, but by smarter operations, stronger collaboration, and technology that enables organizations to deliver access with confidence.
As the Expanded Access community continues to grow, MedaSystems is proud to partner with organizations committed to advancing patient access around the world.
